Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
98.1M
-
Shares change
-
+771K
-
Total reported value, excl. options
-
$1.32B
-
Value change
-
+$3.59M
-
Put/Call ratio
-
0.73
-
Number of buys
-
96
-
Number of sells
-
-62
-
Price
-
$13.43
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2015
202 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2015.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.1M shares
of 124M outstanding shares and own 79.33% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.8M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (8.18M shares), VANGUARD GROUP INC (7.16M shares), BB BIOTECH AG (6.93M shares), FMR LLC (4.94M shares), BlackRock Fund Advisors (4.44M shares), First Eagle Investment Management, LLC (4.06M shares), STATE STREET CORP (3.1M shares), MILLENNIUM MANAGEMENT LLC (3.07M shares), and BlackRock Institutional Trust Company, N.A. (2.72M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.